A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

A systematic review of randomized controlled trials (RCTs) found that weight-loss interventions were associated with improvements in some polycystic ovary syndrome (PCOS) symptoms, including ...

There are a handful of patients in DESTINY-Breast03 with active brain metastasis that were enrolled, and they did look and ...

The FDA approved zolbetuximab (Vyloy) on October 18, 2024, as a first-line treatment for locally advanced unresectable or ...

Fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) is being studied in the frontline setting after data showed that the antibody-drug conjugate (ADC) is promising in previously treated HER2-mutated and ...

“We are excited to present at EORTC-NCI-AACR with data demonstrating how HMBD-802 can potently treat tumors in T-DXd-insensitive settings whilst maintaining an optimal safety profile. I look forward ...

She focused on 2 FDA-approved antibody drug conjugates (ADCs): trastuzumab deruxtecan (T-DXd; Enhertu; Daiichi Sankyo/AstraZeneca) and sacituzumab govitecan (SG), which have both demonstrated ...

Trastuzumab deruxtecan (T-DXd; Enhertu) is an antibody-drug conjugate used as standard therapy for HER2-positive and HER2-low unresectable or metastatic breast cancer. 1 It is classified by the ...